Prostate inhibin peptide (PIP) in prostate cancer: a comparative immunohistochemical study with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP)-Reference-Cited by-同舟云学术

Prostate inhibin peptide (PIP) in prostate cancer: a comparative immunohistochemical study with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP)

Published:1994-04 Issue:1-3 Volume:78 Page:11-17
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Garde Seema V.,Sheth Anil R.,Venkatesan V.M.,Panchal Chandra J.,Porter Arthur T.,Grignon David J.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference31 articles.

1. Histochemistry of the prostate;Allsbrock;Hum. Pathol.,1992

2. Pre-treatment and post-treatment evaluation of prostatic adenocarcinoma for prostatic specific acid phosphatase and prostatic specific antigen by immunohistochemistry;Vernon;J. Urol.,1983

3. Metastatic prostatic carcinoma to supradiaphragmatic lymph nodes;Cho;Am. J. Surg. Pathol.,1987

4. Evidence for the prostatic origin of immunoreactive inhibin like material in human seminal plasma;Beksac;Int. J. Androl.,1984

5. Studies on immunocytochemical localization of inhibin-like material in human prostatic tissue: comparison of its distribution in normal, benign and malignant prostates;Doctor;Br. J. Cancer,1986

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structural and molecular biology of PSP94 Its significance in prostate pathophysiology;Frontiers in Bioscience;2018

2. Testicular Hormones;Basics of Human Andrology;2017

3. Prostate cancer metastasis to the distal phalanx of the left hallux: The first confirmed case and literature review;Oncology Letters;2016-06-13

4. Computational Modeling and Experimental Evaluation of a Novel Prodrug for Targeting the Extracellular Space of Prostate Tumors;Cancer Research;2007-03-01

5. Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer;Anti-Cancer Drugs;2005-11